Plerixafor compared with rc-G-CSF mobilization in study dogs. (A) Median donor mononuclear cell (MNC) chimerism in the first 100 days after HCT in dogs receiving nonmyeloablative conditioning followed by plerixafor-mobilized (dashed line) or rc-G-CSF (solid line) DLA-haploidentical stem cell grafts and posttransplant immunosuppression. (B) Median absolute lymphocyte count (ALC) in dogs receiving plerixafor compared with rc-G-CSF–mobilized PBSC. (C) Median absolute neutrophil count (ANC) in dogs receiving plerixafor compared with rc-G-CSF–mobilized PBSCs.